Be a Smart Investor

Monday, June 1, 2020

Traders May Take A Breather Following Recent Strength

The major U.S. index futures are currently pointing to a roughly flat opening on Monday, with stocks likely to show a lack of direction following the strong upward move seen in May.

from RTT - Market Analysis https://ift.tt/3dmCzvr
via IFTTT

CTI BioPharma Enrolls First Patient In COVID-19 PRE-VENT Phase 3 Trial Of Pacritinib

CTI BioPharma Corp. (CTIC) said Monday it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. The company expects to report topline data from the trial by the end of 2020.

from RTT - Biotech https://ift.tt/2Bgs3Yg
via IFTTT

Eli Lilly Begins Phase 1 Study Of Potential COVID-19 Antibody

Eli Lilly and Company (LLY) said patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from the company's collaboration with AbCellera, in COVID-19 treatment. The patients were dosed at major medical centers in the U.S. under a randomized, placebo-controlled, double-blind trial.

from RTT - Biotech https://ift.tt/2AuUily
via IFTTT

Eli Lilly Says FDA OKs SBLA For Taltz Injection For Non-Radiographic Axial Spondyloarthritis

Eli Lilly and Co. (LLY) announced Monday that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.

from RTT - Biotech https://ift.tt/36NvYrg
via IFTTT

CytoDyn Files For FDA's Priority Review Designation For BLA For Leronlimab - Quick Facts

Biotechnology company CytoDyn Inc. (CYDY.OB) announced Monday that it has filed with the U.S. Food and Drug Administration (FDA) a request seeking Priority Review designation for its Biologics License Application (BLA) for leronlimab as a combination therapy for HIV indication.

from RTT - Biotech https://ift.tt/3dom7L9
via IFTTT

Stock Alert: Moderna Shares Up 4% In Premarket

Shares of Moderna Inc. (MRNA) are currently trading at $64.00, up $2.50 or 4.07% in the pre-market session. The stock has been trading in the range of $11.54 - $87.00 for the past one year, and closed Friday's trade at $61.50, up $5.96 or 10.73%.

from RTT - Before the Bell https://ift.tt/2MkErsu
via IFTTT

Karyopharm In Pursuit Of Wider Use Of Xpovio

After winning FDA nod for Xpovio in the treatment of relapsed or refractory multiple myeloma, Karyopharm Therapeutics Inc. (KPTI) is now awaiting the FDA decision on the same drug for another indication - i.e., in relapsed/refractory diffuse large B-cell lymphoma.

from RTT - Biotech https://ift.tt/2yWzeEo
via IFTTT